578 related articles for article (PubMed ID: 27585283)
21. Stability of APOBEC3F in the Presence of the APOBEC3 Antagonist HIV-1 Vif Increases at the Expense of Co-Expressed APOBEC3H Haplotype I.
Yousefi M; Annan Sudarsan AK; Gaba A; Chelico L
Viruses; 2023 Feb; 15(2):. PubMed ID: 36851677
[TBL] [Abstract][Full Text] [Related]
22. Human APOBEC3 induced mutation of human immunodeficiency virus type-1 contributes to adaptation and evolution in natural infection.
Kim EY; Lorenzo-Redondo R; Little SJ; Chung YS; Phalora PK; Maljkovic Berry I; Archer J; Penugonda S; Fischer W; Richman DD; Bhattacharya T; Malim MH; Wolinsky SM
PLoS Pathog; 2014 Jul; 10(7):e1004281. PubMed ID: 25080100
[TBL] [Abstract][Full Text] [Related]
23. Biochemical analysis of hypermutation by the deoxycytidine deaminase APOBEC3A.
Love RP; Xu H; Chelico L
J Biol Chem; 2012 Aug; 287(36):30812-22. PubMed ID: 22822074
[TBL] [Abstract][Full Text] [Related]
24. APOBEC deaminases-mutases with defensive roles for immunity.
Prochnow C; Bransteitter R; Chen XS
Sci China C Life Sci; 2009 Oct; 52(10):893-902. PubMed ID: 19911124
[TBL] [Abstract][Full Text] [Related]
25. Human activation-induced deaminase lacks strong replicative strand bias or preference for cytosines in hairpin loops.
Sakhtemani R; Perera MLW; Hübschmann D; Siebert R; Lawrence MS; Bhagwat AS
Nucleic Acids Res; 2022 May; 50(9):5145-5157. PubMed ID: 35524550
[TBL] [Abstract][Full Text] [Related]
26. DNA-cytosine deaminases: from antibody maturation to antiviral defense.
Bhagwat AS
DNA Repair (Amst); 2004 Jan; 3(1):85-9. PubMed ID: 14697763
[TBL] [Abstract][Full Text] [Related]
27. [Mutagenic Activity of AID/APOBEC Deaminases in Antiviral Defense and Carcinogenesis].
Shilova ON; Tsyba DL; Shilov ES
Mol Biol (Mosk); 2022; 56(1):55-68. PubMed ID: 35082258
[TBL] [Abstract][Full Text] [Related]
28. Genome-wide mapping of regions preferentially targeted by the human DNA-cytosine deaminase APOBEC3A using uracil-DNA pulldown and sequencing.
Sakhtemani R; Senevirathne V; Stewart J; Perera MLW; Pique-Regi R; Lawrence MS; Bhagwat AS
J Biol Chem; 2019 Oct; 294(41):15037-15051. PubMed ID: 31431505
[TBL] [Abstract][Full Text] [Related]
29. Mouse APOBEC1 cytidine deaminase can induce somatic mutations in chromosomal DNA.
Caval V; Jiao W; Berry N; Khalfi P; Pitré E; Thiers V; Vartanian JP; Wain-Hobson S; Suspène R
BMC Genomics; 2019 Nov; 20(1):858. PubMed ID: 31726973
[TBL] [Abstract][Full Text] [Related]
30. Identification of DNA cleavage- and recombination-specific hnRNP cofactors for activation-induced cytidine deaminase.
Hu W; Begum NA; Mondal S; Stanlie A; Honjo T
Proc Natl Acad Sci U S A; 2015 May; 112(18):5791-6. PubMed ID: 25902538
[TBL] [Abstract][Full Text] [Related]
31. Beyond SHM and CSR: AID and related cytidine deaminases in the host response to viral infection.
Rosenberg BR; Papavasiliou FN
Adv Immunol; 2007; 94():215-44. PubMed ID: 17560276
[TBL] [Abstract][Full Text] [Related]
32. Hepatitis B: modern concepts in pathogenesis--APOBEC3 cytidine deaminases as effectors in innate immunity against the hepatitis B virus.
Bonvin M; Greeve J
Curr Opin Infect Dis; 2008 Jun; 21(3):298-303. PubMed ID: 18448976
[TBL] [Abstract][Full Text] [Related]
33. APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast.
Schumacher AJ; Nissley DV; Harris RS
Proc Natl Acad Sci U S A; 2005 Jul; 102(28):9854-9. PubMed ID: 16000409
[TBL] [Abstract][Full Text] [Related]
34. APOBEC3 Host Restriction Factors of HIV-1 Can Change the Template Switching Frequency of Reverse Transcriptase.
Adolph MB; Ara A; Chelico L
J Mol Biol; 2019 Mar; 431(7):1339-1352. PubMed ID: 30797859
[TBL] [Abstract][Full Text] [Related]
35. Asymmetric Modification of Hepatitis B Virus (HBV) Genomes by an Endogenous Cytidine Deaminase inside HBV Cores Informs a Model of Reverse Transcription.
Nair S; Zlotnick A
J Virol; 2018 May; 92(10):. PubMed ID: 29491156
[TBL] [Abstract][Full Text] [Related]
36. Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases.
Conticello SG; Thomas CJ; Petersen-Mahrt SK; Neuberger MS
Mol Biol Evol; 2005 Feb; 22(2):367-77. PubMed ID: 15496550
[TBL] [Abstract][Full Text] [Related]
37. APOBECs and virus restriction.
Harris RS; Dudley JP
Virology; 2015 May; 479-480():131-45. PubMed ID: 25818029
[TBL] [Abstract][Full Text] [Related]
38. Carboxy-terminal domain of AID required for its mRNA complex formation in vivo.
Nonaka T; Doi T; Toyoshima T; Muramatsu M; Honjo T; Kinoshita K
Proc Natl Acad Sci U S A; 2009 Feb; 106(8):2747-51. PubMed ID: 19196959
[TBL] [Abstract][Full Text] [Related]
39. Cytidine deaminases as a weapon against retroviruses and a new target for antiviral therapy.
Izumi T; Shirakawa K; Takaori-Kondo A
Mini Rev Med Chem; 2008 Mar; 8(3):231-8. PubMed ID: 18336343
[TBL] [Abstract][Full Text] [Related]
40. Degradation of the cancer genomic DNA deaminase APOBEC3B by SIV Vif.
Land AM; Wang J; Law EK; Aberle R; Kirmaier A; Krupp A; Johnson WE; Harris RS
Oncotarget; 2015 Nov; 6(37):39969-79. PubMed ID: 26544511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
